[ad_1]
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies , for the treatment of hematologic malignancies and solid tumor indications, today announced that Marker Therapeutics President and CEO Juan Vera, MD, will attend HC Wainwright 2ND Annual Cell Therapy Virtual Conference. This meeting will be held virtually on March 26, 2024.
Dr. Vera will provide an overview of Marker’s progress and clinical development program on Tuesday, March 26, 2024, at 10 a.m. ET.
Details of the speech are as follows:
event: |
HC Wainwright 2ND Annual Cell Therapy Virtual Conference |
date: |
March 26, 2024, 10 a.m. ET |
Place: |
virtual meeting |
Registration: |
|
This briefing will be replayed on the company’s IR website under “Events and Briefings” starting March 26, 2024.
During the conference, Dr. Vera and members of Marker’s management team will conduct one-on-one meetings with registered investors to present the company’s business and clinical developments, recent achievements and anticipated milestones.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The T cell therapy technology developed by Marker is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens (i.e., tumor targets) and kill tumor cells expressing these targets. This population of T cells is designed to attack multiple tumor targets upon infusion into the patient and activate the patient’s immune system to produce broad-spectrum anti-tumor activity. Because Marker does not genetically modify T cells, Marker believes its product candidates will be easier, cheaper and less toxic to manufacture than current engineered CAR-T and TCR approaches, and could potentially bring meaningful benefits to patients. clinical benefits. As a result, Marker believes its T-cell therapy portfolio has a compelling product profile compared to current genetically modified CAR-T and TCR-based therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.
forward-looking statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this press release regarding Marker’s expectations, plans, business prospects or future performance, and any other statements regarding assumptions or expectations made with respect to any future events, conditions, performance or other matters, are “forward-looking statements” . Forward-looking statements include statements regarding our intentions, beliefs, forecasts, prospects, analyzes or current expectations, including: our research, development and regulatory activities and expectations related to our non-engineered multi-tumor antigen-specific T cell therapies ; the effectiveness or possible range of applications of these regimens and their potential efficacy and safety in treating diseases; and the timing, conduct and success of clinical trials of our product candidates. Forward-looking statements are inherently subject to risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements. Such risks, uncertainties and factors include, but are not limited to, the risks set forth in Marker’s most recent Form 10-K, 10-Q and other SEC filings, which are available through EDGAR at WWW.SEC.GOV. Except as required by law, Marker undertakes no obligation to update its forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this release.
contact method
Tibelund Strategy Consultants
investor
Daniel Cantor-Boateng
(862)213-1398
dboateng@tiberend.com
[ad_2]
Source link